Table 1. Characteristics of randomized controlled trials included in the review.

ESA = Erythropoiesis stimulating agent; ALL = Acute lymphocytic leukemia; NSCLC = Non-small cell lung cancer; SCLC = Small cell lung cancer

Year of study	Drug	Patients sample ESA/Control	Treatment Duration	Concomitant treatment	Types of cancer
Aapro - 2008 [13]	Epoetin beta	463 (231/231)	24 weeks	Chemotherapy	Metastatic breast cancer
Blohmer - 2011 [14]	Epoetin alfa	264 (128/129)	NA	Chemoradiotherapy	Cervical cancer
Cabanillas - 2012 [15]	Epoetin alfa	109 (55/54)	NA	Chemotherapy	ALL, lymphoblastic leukemia, Burkitt lymphoma
Engert - 2010 [16]	Epoetin alfa	1303 (648/655)	NA	Chemotherapy	Advanced stage Hodkin's lymphoma
Fujisaka - 2011 [17]	Epoetin beta	181 (89/92)	12 weeks	Chemotherapy	Lung or gynecological cancer
Gascon - 2019 [18]	Darbepoetin alfa	2516 (1680/836)	NA	Chemotherapy	Stage IV NSCLC
Gupta - 2009 [19]	Epoetin beta	115 (58/57)	Five weeks	Chemoradiotherapy	Advanced cervical cancer
Hernandez - 2009 [20]	Darbepoetin alfa	386 (194/192)	16 weeks	Chemotherapy	Lung, ovarian, cervical, breast, and others
Hoskin - 2009 [21]	Epoetin alfa	300 (151/149)	NA	Radiotherapy	Head and neck cancer
Leyland - Jones - 2016 [22]	Epoetin alfa	2098 (1050/1048)	NA	Chemotherapy	Metastatic breast cancer
Pirker - 2008 [23]	Darbepoetin alfa	600 (301/299)	Nine weeks	Chemotherapy	Extensive stage SCLC
Platzbecker - 2017 [24]	Darbepoetin alfa	146 (97/49)	24 weeks	Chemotherapy	Myelodysplastic syndromes
Pronzato - 2010 [25]	Epoetin alfa	216 (107/109)	Four weeks	Chemotherapy	Breast cancer
Ray Coquard - 2009 [26]	Epoetin alfa	218 (110/108)	12 weeks	Chemotherapy	Non-Hodgkin's lymphoma
Smith Jr - 2008 [27]	Darbepoetin alfa	989 (517/472)	16 weeks	No chemotherapy or radiotherapy	Non-myeloid malignancy
Tsuboi - 2009 [28]	Epoetin beta	120 (62/58)	Eight weeks	Chemotherapy	Lung cancer or malignant lymphoma
Untch - 2011 [29]	Darbepoetin alfa	714 (396/318)	NA	Chemotherapy	Primary breast cancer
Total		10,738